Globus Medical (NYSE:GMED) Issues Quarterly Earnings Results

Globus Medical (NYSE:GMED) announced its earnings results on Thursday. The medical device company reported $1.23 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03, FiscalAI reports. The business had revenue of $763.72 million during the quarter, compared to the consensus estimate of $792.39 million. Globus Medical had a net margin of 17.76% and a return on equity of 14.51%. The firm’s revenue was down .7% on a year-over-year basis. During the same period in the previous year, the company posted $1.18 earnings per share. Globus Medical updated its FY 2026 guidance to 4.950-5.050 EPS.

Here are the key takeaways from Globus Medical’s conference call:

• Q3 revenue declined 0.7% to $763.7 million, as 3% growth in the base business excluding Nevro was offset by Nevro’s 25.7% decline. U.S. Spine grew 2%, held back by delayed product launches and lower-than-expected contributions from competitive recruiting.
• Globus lowered its 2026 revenue outlook to $3.09 billion from $3.18 billion–$3.22 billion, citing Nevro weakness and limited contribution from new products this year. It reiterated non-GAAP EPS guidance of $4.95–$5.05.
• Profitability and cash generation improved despite the revenue decline: non-GAAP EPS rose 4% to $1.23, adjusted gross margin expanded 140 basis points to 69.5%, and free cash flow reached a record $225 million.
• Management expects new spine products—including SCRIPT, XLIF Prone, and eIQ—and greater robot and navigation pull-through to support growth in 2027 and beyond. Enabling Technologies revenue grew 24% in Q3, while deployed units rose 45% year over year.
• The board authorized an additional $500 million share-repurchase program; Globus repurchased $142.9 million of shares in Q3. Management also expects continued margin improvement, while noting that higher R&D investment is planned.

Globus Medical Price Performance

NYSE:GMED traded down $10.77 during mid-day trading on Friday, hitting $70.67. The company’s stock had a trading volume of 9,272,194 shares, compared to its average volume of 1,418,585. Globus Medical has a 1 year low of $70.39 and a 1 year high of $101.40. The stock has a market cap of $9.49 billion, a price-to-earnings ratio of 14.30, a PEG ratio of 1.14 and a beta of 0.98. The business’s fifty day moving average is $77.20 and its two-hundred day moving average is $83.18.

Insiders Place Their Bets

In other news, Director James Tobin sold 30,000 shares of the business’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total value of $2,237,400.00. Following the completion of the transaction, the director owned 15,000 shares of the company’s stock, valued at $1,118,700. The trade was a 66.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Stephen T. Zarrilli sold 25,000 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total value of $2,176,000.00. Following the completion of the sale, the director owned 25,000 shares in the company, valued at $2,176,000. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 60,000 shares of company stock valued at $4,838,400. Company insiders own 18.38% of the company’s stock.

Key Headlines Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, ahead of the $1.20 consensus and up from $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, offering potential support for shareholder returns. Third-quarter results and repurchase announcement
• Neutral Sentiment: Analyst views were mixed: Canaccord and Needham cut their price targets but maintained Buy ratings, while Wells Fargo slightly raised its target and kept an Overweight rating. The company is also seeking acquisitions, though the provided report does not detail potential deals. Report on acquisition plans
• Negative Sentiment: Revenue of $763.7 million missed the $792.4 million analyst estimate and declined 0.7% year over year. Full-year 2026 revenue guidance of $3.1 billion is below the roughly $3.2 billion consensus; management cited spine-product launch delays and weak Nevro sales, weighing on expectations despite EPS guidance being broadly in line. Q3 call highlights and outlook
• Negative Sentiment: BMO Capital Markets downgraded GMED from Outperform to Market Perform and cut its price target, adding to concerns about the outlook. Coverage of the stock decline

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on GMED. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a report on Friday, October 9th. Wall Street Zen lowered shares of Globus Medical from a “buy” rating to a “hold” rating in a research note on Saturday. Royal Bank Of Canada decreased their target price on shares of Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a research report on Thursday, October 1st. Wells Fargo & Company increased their price objective on shares of Globus Medical from $99.00 to $100.00 and gave the company an “overweight” rating in a research report on Friday. Finally, UBS Group began coverage on shares of Globus Medical in a research note on Tuesday, July 28th. They set a “neutral” rating and a $82.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Globus Medical currently has an average rating of “Moderate Buy” and an average target price of $96.92.

About Globus Medical

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.